长江商报消息 ●长江商报记者 黄聪 当下，益佰制药（600594.SH）的经营指标大多正在大滑坡。 1月21日晚间，益佰制药公告显示，公司预计2025年度实现归属于母公司所有者的净利润（简称"归母净 利润"）为-2.85亿元至-3.42亿元；实现归属于母公司所有者的扣除非经常性损益后的净利润（简称"扣 非净利润"）为-2.8亿元至-3.36亿元。 益佰制药介绍，2025年，公司主要产品销售减少，导致公司收入预计下降14%。 2024年4月，益佰制药公告显示，监管部门对公司开展检查时，发现公司涉嫌在艾迪注射液前提取过程 中部分工序未严格按照工艺规程进行操作，不符合《药品生产质量管理规范》的规定，公司被依法立案 调查。 艾迪注射液为益佰制药的核心产品，目前，公司尚未发布其复产消息。 长江商报记者发现，2018年三季度末，益佰制药资产总额达74.65亿元，而截至2025年三季度末，公司 资产总额仅有38.38亿元，7年间减少超过36亿元，降幅约49%，几近腰斩。 归母净利最高预亏3.42亿 长江商报记者发现，近四年来，益佰制药有三年出现巨额亏损。 2022年至2024年，益佰制药营业收入分别为27.35亿元、28. ...

Group 1 - Xiansheng Pharmaceutical has entered into a licensing agreement with NextCure for the ADC drug SIM0505, with a potential transaction value of up to $745 million [1] - SIM0505 targets CDH6 for the treatment of solid tumors, and NextCure will gain access to Xiansheng's TOPOi payload technology for its new ADC product in preclinical development [1] - The National Medical Products Administration has proposed a 30-day review process for innovative drug clinical trial applications to enhance the efficiency of drug development [1] Group 2 - Rongchang Biopharmaceutical's product Tai Tasi Pi has received orphan drug designation from the European Commission for the treatment of myasthenia gravis [2] - Myasthenia gravis is a rare autoimmune disease with a global prevalence of approximately 15-25 cases per 100,000 people [2] Group 3 - Shishi Pharmaceutical Group's caffeine has received the European Pharmacopoeia suitability certificate, facilitating its entry into the European and American markets [3] - The CEP certification indicates compliance with high standards for production processes and quality control, enhancing the brand's international image [3] Group 4 - Saintno Biopharmaceutical expects a significant increase in net profit for the first half of 2025, projecting a year-on-year growth of 253.54% to 332.10% [4] - The growth is attributed to the strong performance of its peptide raw material business and expanded marketing efforts [4]